Galenika continues its portfolio expansion and investments in production

The pharmaceutical company Galenika A.D. assumes the general distribution of Cantabria Labs premium dermocosmetics for the markets of Serbia, Montenegro, and North Macedonia. Cantabria Labs operates in 85 markets worldwide, boasting the highest quality standards and products that are leaders in their categories across Europe.

Last year, Galenika launched 25 products in Serbia and plans to introduce as many as 80 new products throughout 2024. As part of its business internationalization efforts, products were launched in Slovenia and Croatia last year, and representative offices were opened for the Czech and Slovak markets, where the first Galenika products are expected this year.

Galenika significantly expanded its portfolio through the acquisition of LifeMedic, forging a partnership with the Italian manufacturer Pharmalife Research, as well as securing a new premium collaboration agreement with Cantabria Labs from Spain.

“We are strategically focused on strengthening Galenika through the expansion of our own portfolio and establishing partnerships with global manufacturers. During the past year, Galenika initiated a new investment cycle with a focus on further expanding state-of-the-art production capacities and environmental protection. Since 2023, we have invested €18.8 million in the development of three new factories and the reconstruction of the entire internal water supply system, resulting in a 10% reduction in water consumption. Consistent with our development plans, we continue to invest in digitalization and further development of production capacities, alongside expanding our business presence in international markets,” stated Ricardo Vian Markes, CEO of Galenika.